Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

Related Citations for PubMed (Select 15655721)

1.

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.

Ahrén B, Schmitz O.

Horm Metab Res. 2004 Nov-Dec;36(11-12):867-76. Review.

PMID:
15655721
2.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
3.
4.

GLP-1 based therapy for type 2 diabetes.

Arulmozhi DK, Portha B.

Eur J Pharm Sci. 2006 May;28(1-2):96-108. Epub 2006 Feb 20. Review.

PMID:
16488579
5.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

6.

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst JJ.

Expert Opin Emerg Drugs. 2004 May;9(1):155-66. Review.

PMID:
15155141
7.
8.

Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Rotella CM, Pala L, Mannucci E.

J Endocrinol Invest. 2005 Sep;28(8):746-58. Review.

PMID:
16277173
9.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.

Madsbad S.

Eur J Intern Med. 2012 Mar;23(2):132-6. doi: 10.1016/j.ejim.2011.11.003. Epub 2011 Nov 29.

PMID:
22284242
10.

beta-cell failure in diabetes and preservation by clinical treatment.

Wajchenberg BL.

Endocr Rev. 2007 Apr;28(2):187-218. Epub 2007 Mar 12. Review.

PMID:
17353295
11.

Newly approved and promising antidiabetic agents.

Combettes M, Kargar C.

Therapie. 2007 Jul-Aug;62(4):293-310. Epub 2007 Nov 6. Review.

PMID:
17983555
12.
13.

Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

Gallwitz B.

Minerva Endocrinol. 2006 Jun;31(2):133-47. Review.

PMID:
16682937
14.

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Holst JJ.

Diabetologia. 2006 Feb;49(2):253-60. Epub 2006 Jan 14. Review.

PMID:
16416146
15.

Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.

Yamagishi S, Matsui T.

Curr Pharm Des. 2011 Dec;17(38):4379-85. Review.

PMID:
22204436
16.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.

Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.

PMID:
22989472
17.

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.

van Genugten RE, van Raalte DH, Diamant M.

Diabetes Res Clin Pract. 2009 Dec;86 Suppl 1:S26-34. doi: 10.1016/S0168-8227(09)70006-3.

PMID:
20115929
18.

Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

Biol Chem. 2003 Dec;384(12):1543-51.

PMID:
14719796
19.

GLP-1: physiological effects and potential therapeutic applications.

Aaboe K, Krarup T, Madsbad S, Holst JJ.

Diabetes Obes Metab. 2008 Nov;10(11):994-1003. doi: 10.1111/j.1463-1326.2008.00853.x. Epub 2008 Apr 22. Review.

PMID:
18435775
20.

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

Lund A, Knop FK, Vilsbøll T.

Eur J Intern Med. 2014 Jun;25(5):407-14. doi: 10.1016/j.ejim.2014.03.005. Epub 2014 Mar 30. Review.

PMID:
24694879
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk